• Je něco špatně v tomto záznamu ?

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

V. Hungria, M. Beksac, KC. Weisel, AK. Nooka, T. Masszi, I. Spicka, M. Munder, MV. Mateos, TM. Mark, M. Qi, X. Qin, J. Fastenau, A. Spencer, P. Sonneveld, W. Garvin, T. Renaud, KS. Gries

. 2021 ; 193 (3) : 561-569. [pub] 20210208

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025769

In the phase III CASTOR trial, daratumumab, bortezomib and dexamethasone (D-Vd) significantly extended progression-free survival compared with bortezomib and dexamethasone (Vd) alone in patients with relapsed/refractory multiple myeloma (RRMM). Here, we present patient-reported outcomes (PROs) from the CASTOR trial. PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system questionnaire. Treatment effects through Cycle 8 were measured by a repeated measures mixed-effects model. After Cycle 8, PROs were only collected for patients in the D-Vd group who continued on daratumumab monotherapy. Compliance rates for PRO assessments were high and similar between treatment groups. Mean changes from baseline were generally similar between treatment groups for EORTC QLQ-C30 global health status (GHS), functioning and symptoms, and did not exceed 10 points for either treatment group. Subgroup analyses were consistent with the results observed in the overall population. There was no change in patients' health-related quality of life for the first eight cycles of therapy; thereafter, patients treated with daratumumab over the long-term reported improvements in GHS and pain. These results complement the significant clinical benefits observed with D-Vd in patients with RRMM and support its use in this patient population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025769
003      
CZ-PrNML
005      
20211026133528.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17321 $2 doi
035    __
$a (PubMed)33555030
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hungria, Vania $u Santa Casa Medical School, São Paulo, Brazil
245    10
$a Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial / $c V. Hungria, M. Beksac, KC. Weisel, AK. Nooka, T. Masszi, I. Spicka, M. Munder, MV. Mateos, TM. Mark, M. Qi, X. Qin, J. Fastenau, A. Spencer, P. Sonneveld, W. Garvin, T. Renaud, KS. Gries
520    9_
$a In the phase III CASTOR trial, daratumumab, bortezomib and dexamethasone (D-Vd) significantly extended progression-free survival compared with bortezomib and dexamethasone (Vd) alone in patients with relapsed/refractory multiple myeloma (RRMM). Here, we present patient-reported outcomes (PROs) from the CASTOR trial. PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system questionnaire. Treatment effects through Cycle 8 were measured by a repeated measures mixed-effects model. After Cycle 8, PROs were only collected for patients in the D-Vd group who continued on daratumumab monotherapy. Compliance rates for PRO assessments were high and similar between treatment groups. Mean changes from baseline were generally similar between treatment groups for EORTC QLQ-C30 global health status (GHS), functioning and symptoms, and did not exceed 10 points for either treatment group. Subgroup analyses were consistent with the results observed in the overall population. There was no change in patients' health-related quality of life for the first eight cycles of therapy; thereafter, patients treated with daratumumab over the long-term reported improvements in GHS and pain. These results complement the significant clinical benefits observed with D-Vd in patients with RRMM and support its use in this patient population.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x aplikace a dávkování $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a bortezomib $x aplikace a dávkování $7 D000069286
650    _2
$a dexamethason $x aplikace a dávkování $7 D003907
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a biologické modely $7 D008954
650    12
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    12
$a kvalita života $7 D011788
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Beksac, Meral $u Ankara University, Ankara, Turkey
700    1_
$a Weisel, Katja C $u University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Nooka, Ajay K $u Winship Cancer Institute, Emory University, Atlanta, GA, USA
700    1_
$a Masszi, Tamas $u Semmelweis University, Budapest, Hungary
700    1_
$a Spicka, Ivan $u Charles University and General Hospital, Prague, Czech Republic
700    1_
$a Munder, Markus $u Third Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
700    1_
$a Mateos, María-Victoria $u University Hospital of Salamanca/IBSAL, Salamanca, Spain
700    1_
$a Mark, Tomer M $u University of Colorado-Anschutz Medical Campus, Aurora, CO, USA
700    1_
$a Qi, Ming $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Qin, Xiang $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Fastenau, John $u Janssen Research & Development, LLC, Raritan, NJ, USA
700    1_
$a Spencer, Andrew $u Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
700    1_
$a Sonneveld, Pieter $u Erasmus MC Cancer Institute, Rotterdam, the Netherlands
700    1_
$a Garvin, Wendy $u Janssen Research & Development, LLC, Spring House, PA, USA
700    1_
$a Renaud, Thomas $u Janssen Research & Development, LLC, Raritan, NJ, USA
700    1_
$a Gries, Katharine S $u Janssen Research & Development, LLC, Raritan, NJ, USA
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 193, č. 3 (2021), s. 561-569
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33555030 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133534 $b ABA008
999    __
$a ok $b bmc $g 1714692 $s 1146276
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 193 $c 3 $d 561-569 $e 20210208 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace